Skip to main content
Top
Published in: Rheumatology International 12/2013

01-12-2013 | Original Article

Regulatory T cells in Behçet’s disease: Is there a correlation with disease activity? Does regulatory T cell type matter?

Authors: Eren Gündüz, Hava Üsküdar Teke, Nazife Şule Yaşar Bilge, Döndü Üsküdar Cansu, Cengiz Bal, Cengiz Korkmaz, Zafer Gülbaş

Published in: Rheumatology International | Issue 12/2013

Login to get access

Abstract

The aim of this study was to investigate the percentage of regulatory T cells and the correlation with clinical activity in Behçet’s disease. Forty Behçet’s disease (BD) patients, 18 males and 22 females, were included in the study. The patients were diagnosed according to the published BD criteria. Twenty age- and sex-matched volunteer healthy donors were also included. At the time of sampling, clinical activity was assessed for activity signs and symptoms according to the BD Current Activity Form. We considered active those patients with a clinical activity index equal to and/or above 2. Eleven patients had active disease and the remaining were considered as clinically inactive. We have studied the percentages of CD4+CD25+FOXP3+, CD4+CD25+ and CD4+FOXP3+regulatory T cells by flow cytometry and investigated the correlation with disease activity. Percentage of CD4+CD25+FOXP3+Treg in active patients was lower than clinically inactive patients and healthy controls. Percentage of CD4+CD25+Treg was not different between active and inactive patients and healthy controls. Percentage of CD4+FOXP3+Treg was lower than healthy controls in clinically active patients but was not different for inactive group and healthy controls. Patients were active when CD4+CD25+FOXP3+Treg was ≤1.19 %, CD4+CD25+Treg was ≤2.68 %, and CD4+FOXP3+Treg was ≤2.60. CD4+CD25+FOXP3+Treg and CD4+FOXP3+Treg were found negatively correlated with disease activity. Peripheral blood regulatory T cells are decreased in clinically active Behçet’s disease patients. The advances in our understanding of the interactions between distinct subsets of Treg and clinical activity might help in modulating BD treatment.
Literature
1.
2.
go back to reference McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLos Med 3:1242–1248CrossRef McGonagle D, McDermott MF (2006) A proposed classification of the immunological diseases. PLos Med 3:1242–1248CrossRef
3.
go back to reference Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O’Shea JJ et al (2008) CD4+FoxP3+regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 205:1975–1981PubMedCrossRef Andersson J, Tran DQ, Pesu M, Davidson TS, Ramsey H, O’Shea JJ et al (2008) CD4+FoxP3+regulatory T cells confer infectious tolerance in a TGF-beta-dependent manner. J Exp Med 205:1975–1981PubMedCrossRef
4.
go back to reference McMurchy AN, Bushell A, Levings MK, Wood KJ (2011) Moving to tolerance: clinical application of T regulatory cells. Sem Immunol 23:304–313CrossRef McMurchy AN, Bushell A, Levings MK, Wood KJ (2011) Moving to tolerance: clinical application of T regulatory cells. Sem Immunol 23:304–313CrossRef
5.
go back to reference International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080 International Study Group for Behçet’s Disease (1990) Criteria for diagnosis of Behçet’s disease. Lancet 335:1078–1080
6.
go back to reference Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology 38:728–733PubMedCrossRef Bhakta BB, Brennan P, James TE, Chamberlain MA, Noble BA, Silman AJ (1999) Behçet’s disease: evaluation of a new instrument to measure clinical activity. Rheumatology 38:728–733PubMedCrossRef
7.
go back to reference deChambrun MP, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmune Rev 11:687–698CrossRef deChambrun MP, Wechsler B, Geri G, Cacoub P, Saadoun D (2012) New insights into the pathogenesis of Behçet’s disease. Autoimmune Rev 11:687–698CrossRef
8.
go back to reference Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+regulatory T cells. Nat Immunol 4:304–306CrossRef Fontenot JD, Gavin MA, Rudensky AY (2003) Foxp3 programs the development and function of CD4+CD25+regulatory T cells. Nat Immunol 4:304–306CrossRef
9.
go back to reference Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R et al (2007) Activation induced Foxp3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19:345–354PubMedCrossRef Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R et al (2007) Activation induced Foxp3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 19:345–354PubMedCrossRef
10.
go back to reference Nanke Y, Kotake S, Goto M, Ujihara H, Matsubara M, Kamatni N (2008) Decreased percentages of regulatory T cells in peripheral blood of patients with Behçet’s disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol 18:354–358PubMedCrossRef Nanke Y, Kotake S, Goto M, Ujihara H, Matsubara M, Kamatni N (2008) Decreased percentages of regulatory T cells in peripheral blood of patients with Behçet’s disease before ocular attack: a possible predictive marker of ocular attack. Mod Rheumatol 18:354–358PubMedCrossRef
11.
go back to reference Hamzaoui K, Borhani Haghighi A, Ghorbel IB, Houman H (2011) RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet’s disease. J Neuroimmunol 50:249–253CrossRef Hamzaoui K, Borhani Haghighi A, Ghorbel IB, Houman H (2011) RORC and Foxp3 axis in cerebrospinal fluid of patients with neuro-Behçet’s disease. J Neuroimmunol 50:249–253CrossRef
12.
go back to reference Pekiner FN, Aytugar E, Demirel GY, Borahan MO (2012) Interleukin-2, interleukin-6 and T regulatory cells in peripheral blood of patients with Behçet’s disease and recurrent aphthous ulcerations. J Oral Pathol Med 14:73–79CrossRef Pekiner FN, Aytugar E, Demirel GY, Borahan MO (2012) Interleukin-2, interleukin-6 and T regulatory cells in peripheral blood of patients with Behçet’s disease and recurrent aphthous ulcerations. J Oral Pathol Med 14:73–79CrossRef
13.
go back to reference Hamzaoui K (2007) Paradoxical high regulatory T cell activity in Behçet’s disease. Clin Exp Rheumatol 25:107–113 Hamzaoui K (2007) Paradoxical high regulatory T cell activity in Behçet’s disease. Clin Exp Rheumatol 25:107–113
14.
go back to reference Hamzaoui K, Hamzaoui A, Houman H (2006) CD4+CD25+regulatory T cells in patients with Behçet’s disease. Clin Exp Rheumatol 24:71–78 Hamzaoui K, Hamzaoui A, Houman H (2006) CD4+CD25+regulatory T cells in patients with Behçet’s disease. Clin Exp Rheumatol 24:71–78
15.
go back to reference Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D et al (2011) Critical role of IL-21 in modulating T(H)17 and regulatory T cells in Behçet’s disease. J Allergy Clin Immunol 128:655–664PubMedCrossRef Geri G, Terrier B, Rosenzwajg M, Wechsler B, Touzot M, Seilhean D et al (2011) Critical role of IL-21 in modulating T(H)17 and regulatory T cells in Behçet’s disease. J Allergy Clin Immunol 128:655–664PubMedCrossRef
16.
go back to reference Liang L, Wang H, Peng XY, Zhao M (2011) The changes of Th lymphocyte subsets in patients with Behcet disease. Zhonghua Yan Ke Za Zhi 47:393–397PubMed Liang L, Wang H, Peng XY, Zhao M (2011) The changes of Th lymphocyte subsets in patients with Behcet disease. Zhonghua Yan Ke Za Zhi 47:393–397PubMed
17.
go back to reference Mochizuki M, Morita E, Yamamoto S, Yamana S (1997) Characteristics of T cell lines established from skin lesions of Behçet’s disease. J Dermatol Sci 15:9–13PubMedCrossRef Mochizuki M, Morita E, Yamamoto S, Yamana S (1997) Characteristics of T cell lines established from skin lesions of Behçet’s disease. J Dermatol Sci 15:9–13PubMedCrossRef
18.
go back to reference Sugita S, Yamada Y, kaneko S, Horie S, Mochizuki M (2011) Induction of regulatory T cells by infliximab in Behçet’s disease. IOVS 52:476–484 Sugita S, Yamada Y, kaneko S, Horie S, Mochizuki M (2011) Induction of regulatory T cells by infliximab in Behçet’s disease. IOVS 52:476–484
19.
go back to reference Bluestone JA (2005) Regulatory T cell therapy: is it ready for the clinic? Nat Rev Immunol 5:343–349PubMedCrossRef Bluestone JA (2005) Regulatory T cell therapy: is it ready for the clinic? Nat Rev Immunol 5:343–349PubMedCrossRef
20.
go back to reference Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J et al (2004) In vitro expanded antigen specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199:1455–1465PubMedCrossRef Tang Q, Henriksen KJ, Bi M, Finger EB, Szot G, Ye J et al (2004) In vitro expanded antigen specific regulatory T cells suppress autoimmune diabetes. J Exp Med 199:1455–1465PubMedCrossRef
21.
go back to reference Furtado GC, Olivares-Villagomez D, Curotto de Lafaille MA, Wensky AK, Latkowski JA, Lafaille JJ (2001) Regulatory T cells in spontaneous autoimmune encephalomyelitis. Immunol Rev 182:122–134PubMedCrossRef Furtado GC, Olivares-Villagomez D, Curotto de Lafaille MA, Wensky AK, Latkowski JA, Lafaille JJ (2001) Regulatory T cells in spontaneous autoimmune encephalomyelitis. Immunol Rev 182:122–134PubMedCrossRef
22.
go back to reference Shim J, Lee ES, Park S, Bang D, Sohn S (2011) CD4+CD25+regulatory T cells ameliorate Behçet’s disease like symptoms in a Mouse model. Cytotherapy 13:835–847PubMedCrossRef Shim J, Lee ES, Park S, Bang D, Sohn S (2011) CD4+CD25+regulatory T cells ameliorate Behçet’s disease like symptoms in a Mouse model. Cytotherapy 13:835–847PubMedCrossRef
Metadata
Title
Regulatory T cells in Behçet’s disease: Is there a correlation with disease activity? Does regulatory T cell type matter?
Authors
Eren Gündüz
Hava Üsküdar Teke
Nazife Şule Yaşar Bilge
Döndü Üsküdar Cansu
Cengiz Bal
Cengiz Korkmaz
Zafer Gülbaş
Publication date
01-12-2013
Publisher
Springer Berlin Heidelberg
Published in
Rheumatology International / Issue 12/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-013-2835-8

Other articles of this Issue 12/2013

Rheumatology International 12/2013 Go to the issue

ACKNOWLEDGEMENT TO REFEREES

Referees 2012

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.